GlucoLight’s continuous, non-invasive device is a novel approach to glucose monitoring in the acute care environment. Using optical coherence tomography (OCT), the device is able to measure blood glucose levels through a unique anatomical area in the skin that shows physiological changes that directly correlate to changes in blood glucose. The GlucoLight monitor displays real time glucose measurements with an initial single point calibration.
Mr. Krauss continued, “We have developed and demonstrated a device that will provide physicians and health care workers with a product that not only provides continuous data, but will help offset labor and supply costs for hospitals. In recent trials, we have been extremely pleased with the device’s accuracy.”
Blood glucose monitoring has been called “the next vital sign”, linking elevated levels with complications for all patients following surgery. Intensive glucose control protocols, including the “Portland Protocol” developed by Dr. Tony Furnary, have been shown to decrease mortality and morbidity and reduce infections in post cardiac surgery patients.
GlucoLight’s OCGM device is intended to provide an efficient method to monitor patients’ glucose levels in real-time, effectively reducing the time spent on traditional blood testing methods and making it easier to achieve the cost savings associated with intensive glucose control, estimated to be $2,800 per patient.
Mr. Krauss concluded, “Based on compelling data that reinforces the importance of tight glycemic control in the acute care environment, coupled with the worldwide diabetes epidemic, we estimate the size of our near-term addressable market to be at least $500 million. In the coming months, our efforts will focus on additional product refinements to our device for the acute care environment and for eventual FDA evaluation. Eventually, we will miniaturize our glucose monitoring technology and develop a consumer product that will help both Type I and Type II diabetics better manage their glucose levels, and help decrease the complications associated with this world-wide illness.”
Medical Capital Advisors of Boston, MA serves as financial advisor to GlucoLight. The GlucoLight OCGM monitor requires regulatory clearance and is not yet commercially available.
About GlucoLight Corporation: in 2003, GlucoLight is a development-stage company focused on continuous, non-invasive blood glucose monitoring in the acute care environment.
Using Optical Coherence Tomography (OCT), GlucoLight has identified specific physiological targets within the dermis that closely correlate to changes in blood glucose levels. GlucoLight’s OCGM monitor samples these physiological targets every 30 seconds to track blood glucose levels to a high degree of accuracy.
Today, GlucoLight’s OCGM monitor is the only continuous, non-invasive blood glucose monitor for the acute care environment that is in clinical trials.
For more information, visit www.GlucoLight.com.
Press Release Submitted by:
GREGORY | FCA
27 West Athens Avenue, Ardmore, PA 19003
Check out our new website at www.GregoryFCA.com